GW Henssler & Associates’s iBio IBIO Stock Holding History

GW Henssler & Associates’s Portfolio IBIO Stock Details IBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-4	Closed	-$11K	–	166
2014 Q3	$11K	Hold	4	–	–	﹤0.01%	140
2014 Q2	$7K	Buy	+4	New	+$8.65K	﹤0.01%	140

Other funds holding IBIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SignatureFD Atlanta, Georgia $6.53B AUM 20.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

PAMG

Patton Albertson Miller Group Chattanooga, Tennessee $842M AUM 27.94% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

GW Henssler & Associates's IBIO Position: Q4 2014 in Review

GW Henssler & Associates sold out of iBio (IBIO) in Q4 2014, closing a stake of 4 shares — an estimated $11K sold.

GW Henssler & Associates first reported a position in IBIO in Q2 2014 and held it in 2 quarters. The position peaked at $11K in Q3 2014. 20 funds tracked by Wall St. Rank hold IBIO as of Q4 2014.

GW Henssler & Associates reported no remaining iBio position as of Q4 2014 after selling out during the quarter.
GW Henssler & Associates sold 4 iBio shares in Q4 2014, an estimated $11K.
GW Henssler & Associates first reported a position in iBio in Q2 2014 and held it in 2 quarters.
GW Henssler & Associates's iBio position peaked at $11K in Q3 2014.
20 funds tracked by Wall St. Rank held iBio as of Q4 2014.

Based on GW Henssler & Associates's 13F filing for Q4 2014, filed 6 Feb 2015.